Biocon slammed with OAI; Hong Kong looks to WuXi for ADC abilities; Tanvex Pharma launches CDMO services
19 Oct 2023
ADC
Welcome to Endpoints News’ manufacturing roundup, where we bring you essential updates on new builds, collaborations and more.
This week we saw Biocon Biologics in communication with the FDA over an OAI (official action indication) after problematic inspections at its Malaysian facility and new platform launches from the likes of WuXi Biologics and Lallemand Health Solutions.
We zero in on multiple partnerships, including WuXi XDC boosting its bioconjugate capabilities in Hong Kong as well as a few launches and mergers.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.